Aarhus University Seal / Aarhus Universitets segl

SARS-CoV-2 neutralizing antibody responses towards full-length spike protein and the receptor-binding domain

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

  • Rafael Bayarri-Olmos, University of Copenhagen
  • ,
  • Manja Idorn
  • Anne Rosbjerg, University of Copenhagen
  • ,
  • Laura Pérez-Alós, University of Copenhagen
  • ,
  • Cecilie Bo Hansen, University of Copenhagen
  • ,
  • Laust Bruun Johnsen, Novo Nordisk AS
  • ,
  • Charlotte Helgstrand, Novo Nordisk AS
  • ,
  • Franziska Zosel, Novo Nordisk AS
  • ,
  • Jais Rose Bjelke, Novo Nordisk AS
  • ,
  • Fredrik Kryh Öberg, Novo Nordisk AS
  • ,
  • Max Søgaard, International AIDS Vaccine Initiative
  • ,
  • Søren R. Paludan
  • Theresa Bak-Thomsen, Novo Nordisk AS
  • ,
  • Joseph G. Jardine, Expression Biotechnologies
  • ,
  • Mikkel Ole Skjoedt, University of Copenhagen
  • ,
  • Peter Garred, University of Copenhagen

Tools to monitor SARS-CoV-2 transmission and immune responses are needed. We present a neutralization ELISA to determine the levels of Ab-mediated virus neutralization and a preclinical model of focused immunization strategy. The ELISA is strongly correlated with the elaborate plaque reduction neutralization test (ρ = 0.9231, p < 0.0001). The neutralization potency of convalescent sera strongly correlates to IgG titers against SARS-CoV-2 receptor-binding domain (RBD) and spike (ρ = 0.8291 and 0.8297, respectively; p < 0.0001) and to a lesser extent with the IgG titers against protein N (ρ = 0.6471, p < 0.0001). The preclinical vaccine NMRI mice models using RBD and full-length spike Ag as immunogens show a profound Ab neutralization capacity (IC50 5 1.9 3 104 to 2.6 3 104 and 3.9 3 103 to 5.2 3 103, respectively). Using a panel of novel high-affinity murine mAbs, we also show that a majority of the RBD-raised mAbs have inhibitory properties, whereas only a few of the spike-raised mAbs do. The ELISA-based viral neutralization test offers a time- and cost-effective alternative to the plaque reduction neutralization test. The immunization results indicate that vaccine strategies focused only on the RBD region may have advantages compared with the full spike.

Original languageEnglish
JournalJournal of Immunology
Volume207
Issue3
Pages (from-to)878-887
Number of pages10
ISSN0022-1767
DOIs
Publication statusPublished - Aug 2021

Bibliographical note

Publisher Copyright:
Copyright © 2021 by The American Association of Immunologists, Inc. All rights reserved.

See relations at Aarhus University Citationformats

ID: 221363429